ContraFect_LOGO_Web.jpg
ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st ECCMID
July 19, 2021 07:31 ET | ContraFect Corporation
YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity
July 19, 2021 07:30 ET | ContraFect Corporation
YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development
June 17, 2021 07:31 ET | ContraFect Corporation
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum
June 17, 2021 07:30 ET | ContraFect Corporation
YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin for Potential Treatment of Prosthetic Joint Infections
May 26, 2021 07:30 ET | ContraFect Corporation
Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function The observed clinical responses in patients...
ContraFect_LOGO_Web.jpg
ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update
May 14, 2021 07:30 ET | ContraFect Corporation
Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021 BARDA contract award provides up to $86.8 million for exebacase...
ContraFect_LOGO_Web.jpg
ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Office
May 03, 2021 07:30 ET | ContraFect Corporation
YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Invited to Participate in the Cystic Fibrosis Target Product Profile Virtual Symposium
April 26, 2021 07:30 ET | ContraFect Corporation
YONKERS, N.Y., April 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit
April 15, 2021 18:30 ET | ContraFect Corporation
YONKERS, N.Y., April 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents...
ContraFect_LOGO_Web.jpg
ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
March 30, 2021 07:30 ET | ContraFect Corporation
Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021 Biomedical Advanced Research...